NEWTON, Mass.--(BUSINESS WIRE)--Pro-Pharmaceuticals, Inc. (Amex:PRW), a company "Advancing Drugs Through Glycoscience®", today announced that Boston Medical Center (BMC) began dosing patients in a Phase II clinical trial of DAVANAT® with 5-Fluorouracil (5-FU) to treat patients with advanced bile duct and gallbladder cancers.
